The European Patent Organisation (EPO) issued a patent to Bavarian Nordic that protects the company's MVA-BN technology.

The patent belongs to the same patent family as the earlier-issued US patents (USP 6,791,893 and USP 6,913,752) and covers the MVA-BN virus and derivatives hereof with the same biological characteristics and safety profile as well as recombinant viruses hereof. The patent gives Bavarian Nordic the sole right to produce, market and sell MVA-BN, and derivatives hereof with the same biological characteristics and safety profile as well as recombinant viruses hereof in Europe, claims a company release.

MVA-BN is a multivalent vaccine vector for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast, colon and prostate cancer. Several MVA-BN-based HIV and smallpox vaccines are in clinical phase I and phase II trials.

Bavarian Nordic A/S is a leading international biopharmaceutical company developing, producing and marketing innovative vaccines to prevent and treat infectious diseases and cancer.